The Lundquist Institute

The Lundquist Institute’s Investigator Dr. Ashraf Ibrahim and his colleagues paper published in Nature Microbiology on translational potential of novel immunotherapies against lethal fungal infection. The authors propose the name mucoricin for the toxin that helps facilitate infection of fungi that causes mucormycosis and they also indicate that it is a promising therapeutic target to combat the lethal effect of the fungi. https://lundquist.org//lundquist-research-lead-author-grou

Now accepting applications for Fall 2021! The Lundquist Institute PhD Program in Translational Research will train both clinicians and traditional graduate students to enjoy careers whose defining characteristic is the ability to navigate from the bench to the bedside. 4 Year Time-to-Degree... $37,000 Annual Stipend Graduate Housing Available No Application Fee Application Deadline: January 29, 2021 More information at https://lundquist.org/gradprogram.

Lundquist Institute CEO Dr. David Meyer says, 2020 will go down in the record books. We were able to navigate with agility through the unprecedented pandemic and demonstrated our values when faced with exceptional challenges. I applaud our investigators, our administrative team, and all our employees for pivoting rapidly and strategically while moving ahead with our key priorities. I invite our community and the public to view our Year in Review video which highlights our remarkable successes this past year. https://lundquist.org//lundquist-institute-releases-its-20

Lundquist Institute President and CEO Dr. David Meyer encourages you to support local restaurants by considering takeout during the current stay-at-home order. Watch his new cooking series with local chefs: https://lundquist.org/community-outreach/cooking-with-class.

Why give to The Lundquist Institute? Discover our past, present, and future. Our crucial work is not possible without supporters like you. https://lundquist.org/about https://lundquist.org/donate

The visitors in the lobby of our MRL building would like you all to have a happy and safe Halloween Weekend. https://www.cdph.ca.gov//Guidance-for-Safer-Halloween-and-

We are proud to have been selected as one of the national sites for multiple COVID-19 trials. Our investigators are on the front lines, fighting this global pandemic. Don’t forget, Giving Day 2020 at the Lundquist Institute is Tuesday, December 1. Mark your calendar!

Giving Day 2020 at the Lundquist Institute is Tuesday, December 1. Every dollar you give supports our groundbreaking research and breakthrough innovations. Learn more at https://lundquist.org.

The President is reported to have COVID-19 and to be receiving remdesivir and an investigational SARS-CoV-2 (virus causing COVID-19) neutralizing monoclonal antibody cocktail developed by Regeneron Pharmaceuticals. Many are wondering what this is all about. Remdesivir is given to select hospitalized patients to reduce duration of symptoms in those with COVID-19. On September 16, 2020 Eli Lilly and Company, and on September 29, 2020 Regeneron Pharmaceuticals reported very ear...ly evidence of potential benefits of their respective SARS-CoV-2 monoclonal antibodies in outpatients with COVID-19. There is little data supporting the use of the regimen being given to the President, and no data using these drugs in combination. Carefully conducted studies will ultimately define the safest and most effective way to manage outpatients with COVID-19. Although the circumstances are most unfortunate, they do provide an important call out for good science!

Join us tonight at 6 PM PDT for the 2nd Lundquist Institute Community Science Series, a panel discussion webinar on COVID19: Pregnancy, Infants, and Children. Register at https://lundquist.org//covid-19-pregnancy-infants-and-chil or watch the live stream on our Facebook page.

Listen to the Institute's Dr. Merritt Schreiber on Jefferson Exchange on Jefferson Public Radio talking about ways to approach and assist wildfire victims. https://www.ijpr.org//thu-9-am-working-to-prevent-fire-tra

We are delighted to invite you to join us for the second Lundquist Community Science Series panel discussion, entitled COVID-19: Pregnancy, Infants, and Children. This webinar, scheduled to take place on Wednesday, September 30th at 6:00 p.m., PDT, will be moderated by our President and CEO, Dr. David Meyer. Participants will once again be provided with the opportunity to hear from, as well as ask questions of, our world-renowned investigators and clinician scientists: So...nia Kaur Dargan, M.D. Chief, Pediatric Hospital Medicine Director Normal Newborn Services Department of Pediatrics Harbor-UCLA Medical Center Kristina D. Galyon, D.O. Obstetrician-Gynelcologist Maternal-Fetal Medicine Specialist Harbor-UCLA Medical Center Lynne M. Smith, M.D. Investigator, The Lundquist Institute Chair, Department of Pediatrics Harbor-UCLA Medical Center Ken M. Zangwill, M.D. Investigator, The Lundquist Institute Chief, Infectious Diseases Department of Pediatrics Harbor-UCLA Medical Center

"Researchers at Dartmouth (in collaboration with those at The Lundquist Institute at Harbor-UCLA Medical Center, Lyticon and Stealth Biologics) engineered and patented F12, a new lysin-based antibacterial agent."

https://losangeles.cbslocal.com//hopefully-this-is-going-/

We began phase 3 trials of the University of OxfordAstraZeneca COVID-19 vaccine trial yesterday, September 4. The vaccine is called AZD1222 and has already gone through early trials. This trial is designed to determine whether the vaccine can prevent symptomatic COVID-19 after two doses. The study aims to enroll 30,000 volunteers across the United States. It is important to note that this vaccine does not have a live virus and cannot give a person COVID-19. If the results from the trial are positive, the vaccine could be made available to the public to prevent disease. The first participant to receive an injection in Los Angeles was Jorge Vega, a 62-year-old, Latinx male who works as a waiter in Los Angeles who said, To my community, I say don't be afraid. This is for the well-being of humanity.